The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers
Open accessAbstract
Deregulation of the cell cycle machinery is a hallmark of cancer. While CDK4/6 inhibitors are FDA approved (palbociclib) for treating advanced estrogen receptor-positive breast cancer, two major clinical challenges remain: (i) adverse events leading to therapy discontinuation and (ii) lack of reliable biomarkers. Here we report that breast cancer cells activate autophagy in response to palbociclib, and that the combination of autophagy and CDK4/6 inhibitors induces irreversible growth inhibition and senescence in vitro, and diminishes growth of cell line and patient-derived xenograft tumours in vivo. Furthermore, intact G1/S transition (Rb-positive and low-molecular-weight isoform of cyclin E (cytoplasmic)-negative) is a reliable prognostic biomarker in ER positive breast cancer patients, and predictive of preclinical sensitivity to this drug combination. Inhibition of CDK4/6 and autophagy is also synergistic in other solid cancers with an intact G1/S checkpoint, providing a novel and promising biomarker-driven combination therapeutic strategy to treat breast and other solid tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
De Cillà, S. D., Farruggio, S., Vujosevic, S., Raina, G., Filippini, D., Gatti, V., Clemente, N., Mary, D., Vezzola, D., Casini, G., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479441 · Cited by 5,136
Autophagy: cellular and molecular mechanisms
Glick, D., Barth, S., & Macleod, K. F. (2010) · The Journal of Pathology · doi:10.1002/path.2697 · Cited by 3,802
Bcl-2 Antiapoptotic Proteins Inhibit Beclin 1-Dependent Autophagy
Pattingre, S., Tassa, A., Qu, X., Garuti, R., Liang, X. H., Mizushima, N., Packer, M., Schneider, M. D., & Levine, B. (2005) · Cell · doi:10.1016/j.cell.2005.07.002 · Cited by 3,536
The Beclin 1 network regulates autophagy and apoptosis
Kang, R., Zeh, H. J., Lotze, M. T., & Tang, D. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2010.191 · Cited by 2,485
Kimura, S., Noda, T., & Yoshimori, T. (2007) · Autophagy · doi:10.4161/auto.4451 · Cited by 2,278
The essence of senescence: Figure 1.
Kuilman, T., Michaloglou, C., Mooi, W. J., & Peeper, D. S. (2010) · Genes & Development · doi:10.1101/gad.1971610 · Cited by 2,038
8-hydroxy-2′ -deoxyguanosine (8-OHdG): A Critical Biomarker of Oxidative Stress and Carcinogenesis
VALAVANIDIS, A., VLACHOGIANNI, T., & FIOTAKIS, C. (2009) · Journal of Environmental Science and Health, Part C · doi:10.1080/10590500902885684 · Cited by 1,978
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Cited by
Onorati, A. V., Dyczynski, M., Ojha, R., & Amaravadi, R. K. (2018) · Cancer · doi:10.1002/cncr.31335 · Cited by 837
Self-citationTargeting CDK4 and CDK6 in cancer
Goel, S., Bergholz, J. S., & Zhao, J. J. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00456-3 · Cited by 531
Senescent Cells in Cancer Therapy: Friends or Foes?
Wang, B., Kohli, J., & Demaria, M. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.05.004 · Cited by 508
CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest
Goel, S., DeCristo, M. J., McAllister, S. S., & Zhao, J. J. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.07.002 · Cited by 501
Lysosome biogenesis: Regulation and functions
Yang, C., & Wang, X. (2021) · Journal of Cell Biology · doi:10.1083/jcb.202102001 · Cited by 473
CDK4 and CDK6 kinases: From basic science to cancer therapy
Fassl, A., Geng, Y., & Sicinski, P. (2022) · Science · doi:10.1126/science.abc1495 · Cited by 464
Turner, N. C., Liu, Y., Zhu, Z., Loi, S., Colleoni, M., Loibl, S., DeMichele, A., Harbeck, N., André, F., Bayar, M. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00925 · Cited by 449
Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
Álvarez-Fernández, M., & Malumbres, M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.010 · Cited by 390
Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
Pandey, K., An, H., Kim, S. K., Lee, S. A., Kim, S., Lim, S. M., Kim, G. M., Sohn, J., & Moon, Y. W. (2019) · International Journal of Cancer · doi:10.1002/ijc.32020 · Cited by 361
Fasting-mimicking diet and hormone therapy induce breast cancer regression
Caffa, I., Spagnolo, V., Vernieri, C., Valdemarin, F., Becherini, P., Wei, M., Brandhorst, S., Zucal, C., Driehuis, E., Ferrando, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2502-7 · Cited by 355
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
Pellarin, I., Dall’Acqua, A., Favero, A., Segatto, I., Rossi, V., Crestan, N., Karimbayli, J., Belletti, B., & Baldassarre, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02080-z · Cited by 304
The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer
Hickey, T. E., Selth, L. A., Chia, K. M., Laven-Law, G., Milioli, H. H., Roden, D., Jindal, S., Hui, M., Finlay-Schultz, J., Ebrahimie, E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01168-7 · Cited by 257
Immunomodulation by anticancer cell cycle inhibitors
Petroni, G., Formenti, S. C., Chen-Kiang, S., & Galluzzi, L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0300-y · Cited by 163
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS- Mutant Pancreatic Cancer
Goodwin, C. M., Waters, A. M., Klomp, J. E., Javaid, S., Bryant, K. L., Stalnecker, C. A., Drizyte-Miller, K., Papke, B., Yang, R., Amparo, A. M., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-0391 · Cited by 168
Senescence as a therapeutically relevant response to CDK4/6 inhibitors
Wagner, V., & Gil, J. (2020) · Oncogene · doi:10.1038/s41388-020-1354-9 · Cited by 148
Senolytics for Cancer Therapy: Is All that Glitters Really Gold?
Carpenter, V. J., Saleh, T., & Gewirtz, D. A. (2021) · Cancers · doi:10.3390/cancers13040723 · Cited by 124
Lysosomal trapping of palbociclib and its functional implications
Llanos, S., Megias, D., Blanco-Aparicio, C., Hernández-Encinas, E., Rovira, M., Pietrocola, F., & Serrano, M. (2019) · Oncogene · doi:10.1038/s41388-019-0695-8 · Cited by 96
Non-cell autonomous effects of the senescence-associated secretory phenotype in cancer therapy.
Saleh, T., Tyutynuk-Massey, L., Cudjoe, E. K., Idowu, M. O., Landry, J. W., & Gewirtz, D. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00164 · Cited by 85
Duro-Sánchez, S., Nadal-Serrano, M., Lalinde-Gutiérrez, M., Arenas, E. J., Bernadó Morales, C., Morancho, B., Escorihuela, M., Pérez-Ramos, S., Escrivá-de-Romaní, S., Gandullo-Sánchez, L., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0787 · Cited by 45
Brandariz, J., de Llobet, L., Esquefa, V., Aguilar, D., Salca, A., Arce-Gallego, S., Cresta Morgado, P., Sole, A., Agundez, L., Mir, G., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0903 · Cited by 5
Duro-Sánchez, S., Nadal-Serrano, M., Lalinde-Gutiérrez, M., Arenas, E. J., Bernadó Morales, C., Morancho, B., Escorihuela, M., Pérez-Ramos, S., Escrivá-de-Romaní, S., Gandullo-Sánchez, L., et al. (2023) · doi:10.1158/0008-5472.c.6514164
Metadata
- Authors
- Vijayaraghavan, S., Karakas, C., Doostan, I., Chen, X., Bui, T., Yi, M., Raghavendra, A. S., Zhao, Y., Bashour, S. I., Ibrahim, N. K., Karuturi, M., Wang, J., Winkler, J. D., Amaravadi, R. K., Hunt, K. K., Tripathy, D., & Keyomarsi, K.
- Venue
- Nature Communications
- Published
- 2017-06-27
- Volume
- 8
- Issue
- 1
- Pages
- 15916-15916
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2678824027
- Cited by
- 292
- References
- 69
- FWCI
- 22.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.